Spatial Transcriptomics Reveal Pitfalls and Opportunities for the Detection of Rare High-Plasticity Breast Cancer Subtypes

Lab Invest. 2023 Dec;103(12):100258. doi: 10.1016/j.labinv.2023.100258. Epub 2023 Oct 7.

Abstract

Breast cancer is one of the most prominent types of cancers, in which therapeutic resistance is a major clinical concern. Specific subtypes, such as claudin-low and metaplastic breast carcinoma (MpBC), have been associated with high nongenetic plasticity, which can facilitate resistance. The similarities and differences between these orthogonal subtypes, identified by molecular and histopathological analyses, respectively, remain insufficiently characterized. Furthermore, adequate methods to identify high-plasticity tumors to better anticipate resistance are lacking. Here, we analyzed 11 triple-negative breast tumors, including 3 claudin-low and 4 MpBC, via high-resolution spatial transcriptomics. We combined pathological annotations and deconvolution approaches to precisely identify tumor spots, on which we performed signature enrichment, differential expression, and copy number analyses. We used The Cancer Genome Atlas and Cancer Cell Line Encyclopedia public databases for external validation of expression markers. By focusing our spatial transcriptomic analyses on tumor cells in MpBC samples, we bypassed the negative impact of stromal contamination and identified specific markers that are neither expressed in other breast cancer subtypes nor expressed in stromal cells. Three markers (BMPER, POPDC3, and SH3RF3) were validated in external expression databases encompassing bulk tumor material and stroma-free cell lines. We unveiled that existing bulk expression signatures of high-plasticity breast cancers are relevant in mesenchymal transdifferentiated compartments but can be hindered by abundant stromal cells in tumor samples, negatively impacting their clinical applicability. Spatial transcriptomic analyses constitute powerful tools to identify specific expression markers and could thus enhance diagnosis and clinical care of rare high-plasticity breast cancers.

Keywords: diagnostic markers; integrative approaches; plasticity; rare subtypes; spatial transcriptomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast / metabolism
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • Carrier Proteins / metabolism
  • Cell Adhesion Molecules / metabolism
  • Claudins / metabolism
  • Female
  • Gene Expression Profiling
  • Humans
  • Muscle Proteins / metabolism
  • Prognosis
  • Transcriptome
  • Triple Negative Breast Neoplasms* / pathology
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Claudins
  • BMPER protein, human
  • Carrier Proteins
  • POPDC3 protein, human
  • Muscle Proteins
  • Cell Adhesion Molecules
  • SH3RF3 protein, human
  • Ubiquitin-Protein Ligases